Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Yaki Saciu, Jennifer Kertes, Naama Shamir Stein, and Anat Ekka Zohar

Division of Data and Digital Health, Maccabi HealthCare Services, Tel Aviv–Jaffa, Israel

A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January–February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August–October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%–93.2%) and adjusted VE was 89.1% (95% CI, 87.5%–90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.

**Keywords.** vaccine effectiveness; COVID-19; SARS-CoV-2; Pfizer-BioNTech vaccine; mRNA BNT162b2.

The United States (US) Food and Drug Administration announced emergency approval for the use of the BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in December 2020 [1] after the vaccine developer reported 95% vaccine effectiveness (VE) [2]. In that same month, Israel rolled out a national vaccination campaign using the BNT162b2 vaccine (2-dose schedule with a 21-day interval) for the population aged ≥16 years. By April 2021, >50% of those aged ≥16 years and 88% of those aged ≥50 years had been fully vaccinated, with the number of new cases (7-day average) dropping to 140 per day by April 2021 [3]. Initial population-based studies in Israel comparing the vaccinated and unvaccinated reported VE rates of 95% [4, 5]. The Alpha variant was the predominant variant at the time of the vaccination drive. However, Israel experienced a new wave of Delta variant–based infection from mid-June 2021.

The Israel Ministry of Health implemented a second national vaccination campaign in August 2021, providing a third dose of the BNT162b2 vaccine, after studies [6] indicated that protection against SARS-CoV-2 was waning 6 months after the first national vaccination campaign. Both national campaigns initially targeted the population aged ≥60 years, broadening the age bracket of the target population, on a week-to-week basis. To determine VE against SARS-CoV-2 infection of the additional dose, we carried out a retrospective cohort study, based on data extracted from the database of Maccabi HealthCare Services (the second-largest health maintenance organization [HMO] in Israel). We compared infection rates during August to mid-October 2021 (70-day period) between those vaccinated (2 doses) in the first months of the first vaccine campaign with those receiving the third dose in the second national campaign.

**METHODS**

**Study Population**

The study population was drawn from all active HMO members who did not leave the HMO during the study period and had no evidence of infection (positive polymerase chain reaction test [PCR] or immunoglobulin G serology) prior to day 7 postvaccination of last dose and up to the start of the study period (7 August 2021). The study population was comprised of 2 groups: those who had received 2 doses of the vaccine and were at least 7 days post–second vaccination in January–February 2021 (herein referred to as the “2-dose group”), and those who had received the third dose of the vaccine (July to mid-October 2021) and were at least 7 days postvaccination (herein referred to as the “3-dose group”). The groups were dynamic, such that persons in the 2-dose group contributed days to the 2-dose group up until vaccination with the third dose, and contributed days to the third dose group from day 8 after third vaccination, providing that they had not been infected or died in the intervening period. Unvaccinated members and members receiving only 1 dose were excluded from the study.

**Outcome and Covariate Measures**

Having a positive PCR result in the 70 days of follow-up (7 August 2021–15 October 2021) was the outcome variable. Other measures were age group, gender, socioeconomic status (SES), population group (Other/Arab), and religiosity (Orthodox Jew/Other). SES, population group, and religiosity are all based on census and national survey classifications applied to home address.

**Statistical Analysis**

Incidence rates were calculated as number of first positive PCR results per 1000 person-days. For the 3-dose group, number of participants for which each participant was calculated from day 8 after receipt
of the third dose to the earliest of the following endpoints: first PCR-positive result, death, and end of the follow-up period (15 October 2021). For the 2-dose group, number of days was calculated from the start of the follow-up period (7 August 2021) to the earliest of the following endpoints: first PCR-positive result, death, and end of the follow-up period. Crude VE rates were calculated as follows: 1 – (incidence rate in 3-dose group / incidence rate in 2-dose group). These rates were adjusted using 2 different methods. First the 3-dose group was matched by age group, gender, SES, population group, and religiosity to the 2-dose group. Second, a Generalized Linear Models (GLM) model (Poisson) was used that included calendar period (10-day consecutive periods) in addition to the factors described above. Calendar period was included to allow for the rapidly changing risk of infection over time. Crude and adjusted analyses were repeated twice: stratified by age and stratified by number of follow-up days. Analyses were carried out using R software, version 3.6.2. Confidence intervals (CIs) were calculated as 95% confidence levels. The study was carried out in August 2021 after being approved by the Maccabi HealthCare Services institutional review board and Helsinki committee (number 0178-20-MHS) and was exempted from informed consent.

RESULTS

Of the 947,131 members meeting the study criteria, 8.6% received only 2 doses of the vaccine in January–February 2021 and 91.4% received a third dose of the vaccine between July and mid-October 2021. Of the 865,877 persons receiving the third dose, 83.6% received the third dose during the study follow-up period and thus contributed days to both the 2-dose and 3-dose groups in VE analyses. Demographic characteristics of the study population (Table 1) have therefore been split into 3 groups: “only 2-dose” (only contributed days to the 2-dose group); “became 3-dose” (those who contributed days to both the 2-dose and 3-dose groups); and “only 3-dose” (those who only contributed days to the 3-dose group). Individuals in the study group receiving only 2 doses of the vaccine were more likely to be younger and from a lower socioeconomic bracket and more likely to be from minority groups (Arab and Orthodox Jew).

Incidence rate and crude and adjusted VE rates are presented in Table 2. Crude VE rates were slightly higher (92.9% [95% CI, 92.6%–93.2%]) than adjusted VE rates (89.1% [95% CI, 87.5%–90.5%]). When stratified by age group, crude VE rates were 1.9% higher for the under-60 age group compared to the ≥60 age group (Table 2). Adjusted VE rates were lower than crude rates for both age groups, with difference in adjusted VE attenuated between the 2 age groups (<60 years: 88.4% [95% CI, 87.7%–89.1%]; ≥60 years: 87.7% [95% CI, 86.4%–88.8%]). When stratified by number of follow-up days, crude VE for study participants with the later follow-up period was 2.8% higher than for those with the earlier follow-up period (Table 2). Adjusted rates were again lower than crude rates for both groups and evidenced a smaller difference between groups.

Table 1. Demographic Characteristics of the Study Population by Dose Group, October 2021, Maccabi HealthCare Services, Israel

| Characteristic                  | Only 2-Dose Groupa (n = 81,244) | Became 3-Dose Groupb (n = 724,540) | Only 3-Dose Groupc (n = 141,347) |
|--------------------------------|---------------------------------|-----------------------------------|---------------------------------|
| Gender                         |                                 |                                   |                                 |
| Male                           | 39,266 (48.3)                   | 346,837 (47.9)                    | 72,251 (51.1)                   |
| Female                         | 41,978 (51.7)                   | 377,703 (52.1)                    | 69,096 (48.9)                   |
| Age group, y                   |                                 |                                   |                                 |
| 0–17                           | 3,983 (4.9)                     | 2,179 (3.1)                       | 0 (0)                           |
| 18–29                          | 17,355 (21.4)                   | 86,474 (11.9)                     | 23 (0.0)                        |
| 30–44                          | 23,504 (28.9)                   | 173,861 (24.0)                    | 86 (0.1)                        |
| 45–59                          | 23,555 (29.0)                   | 286,546 (39.5)                    | 444 (0.3)                       |
| 60–74                          | 9,299 (11.4)                    | 116,545 (16.1)                    | 99,825 (70.6)                   |
| ≥75                            | 35,48 (4.4)                     | 38,905 (5.4)                      | 40,969 (29.0)                   |
| Socioeconomic status           |                                 |                                   |                                 |
| Low                            | 18,120 (22.3)                   | 84,517 (11.7)                     | 15,353 (10.9)                   |
| Middle                         | 40,399 (49.7)                   | 352,140 (48.7)                    | 68,715 (48.6)                   |
| High                           | 22,725 (28.0)                   | 287,883 (39.7)                    | 57,279 (40.5)                   |
| Population group               |                                 |                                   |                                 |
| Other                          | 74,720 (92.0)                   | 701,055 (96.8)                    | 138,646 (98.1)                  |
| Arab                           | 6524 (8.0)                      | 23,485 (3.2)                      | 2701 (1.9)                      |
| Religiosity                    |                                 |                                   |                                 |
| Other                          | 74,020 (91.1)                   | 696,195 (96.1)                    | 137,053 (97.0)                  |
| Orthodox Jew                   | 7224 (8.9)                      | 28,345 (3.9)                      | 4294 (3.0)                      |

Data are presented as No. (%).
Abbreviation: SES, socioeconomic status.
*a* Only contributed days to the 2-dose group.
*b* Contributed days to both the 2-dose and 3-dose groups.
*c* Only contributed days to the 3-dose group.
(1–35 days: 88.9% [95% CI, 88.2%–89.6%]; 36–70 days: 89.1% [95% CI, 87.5%–90.5%]). From the GLM model of the total study population, other measures associated with infection outcome, independent of number of doses received, were calendar period, age group, SES, population group, and religiosity. The risk of infection increased 1.5-fold (95% CI, 1.45- to 1.57-fold) in the first 30 days (third 10-day period compared to first 10-day period), decreasing 0.28-fold in the seventh 10-day period (95% CI, .25- to .31-fold). Risk of infection increased with decreasing age. Orthodox Jews had a 1.93-fold higher risk of infection (95% CI, 1.82- to 2.03-fold), whereas the Arab population had an 0.65-fold lower risk (95% CI, .60- to .70-fold). Risk of infection increased with decreasing SES; compared to those with high SES, the risk was 1.25-fold higher (95% CI, 1.21–1.29) for middle SES and 1.48-fold higher (95% CI, 1.40–1.55) for low SES.

**DISCUSSION**

The findings presented here indicate that providing an additional dose of BNT162b2 vaccine 6 months after initial 2-dose vaccination bolsters protection against infection, with a VE of 89%. The decision to revaccinate with a third dose appears, at this early stage, to have been a good decision.

Evidence from Israel (Kertes et al, preprint data [7]) and the US [6] has shown that vaccination with 2 doses of BNT162b2 drops over a 6-month period. Given that the majority of Israel's population was vaccinated within months of the first campaign, comparison of 3 doses with an unvaccinated population was not carried out, given the large bias potential of those choosing not to be vaccinated. While VE drops over time, the 2-dose regimen would still confer protection for at least some of the population, and therefore we consider an 89% VE to be an excellent outcome.

Our findings are comparable with other studies carried out in Israel. In a national study, focusing on the 60-and-over population, with a maximum follow-up period of 31 days, the adjusted VE rate was 89.7% [8]. Another Israeli HMO study that followed up members aged ≥40 years for a maximum 20-day period also found a reduction in infection rates of between 70% and 84% [9]. The longer follow-up period in the present study indicates that while the risk of infection increased in the first month of follow-up, rates of infection dropped by the second month. We suggest that the initial rise reflects the surge in infections at the beginning of the infection wave, and that the drop reflects the impact of the vaccine on overall infection rates.

Given that the majority of infection in the current wave in Israel is due to the Delta variant, we suggest that the high VE found here indicates that the majority of the fourth wave of infection was secondary to the declining effectiveness of the initial 2 doses and not because of introduction of the Delta virus. In a large US study, Tartof et al [6] did not find significant differences in VE decline between those infected with the Delta virus and those infected with other variants.

Although encouraging, these results are based on a relatively short follow-up period. Although the findings were age-adjusted, the age group ≥60 years was overrepresented among persons who received the third vaccine dose, and a longer follow-up period may provide a more balanced result. Both the decision to vaccinate and to carry out a PCR test are voluntary, and bias cannot be ruled out. Despite these limitations, the findings here indicate that introduction of the third dose was effective in reducing SARS-CoV-2 infection rates in Israel.

**Notes**

**Disclaimer.** The sponsor had no role in the study design, collection, analysis and interpretation of the data, writing of the article, or decision to submit the report for publication.

---

**Table 2. Crude and Adjusted Vaccine Effectiveness Rates, Comparing 3-Dose With 2-Dose Receipt of BNT162b2 Vaccine, August to Mid-October 2021, Maccabi HealthCare Services, Israel**

| Measure          | Population group | Total No. of Person-Days | Total No. of PCR-Positive Persons | Incidence/1000 Person-Days | VE, % (95% CI) |
|------------------|------------------|--------------------------|----------------------------------|-----------------------------|---------------|
| Crude rates      | Total population | 2-dose 19,845,270        | 17,830                           | 0.90                        | 92.9 (92.6–93.2) |
|                  |                  | 3-dose 39,537,837        | 2512                             | 0.06                        |               |
| Age <60 y        | 2-dose 17,542,277| 16,451                   | 0.94                             | 92.6 (92.2–93.0)            |               |
|                  | 3-dose 22,627,091| 1566                     | 0.07                             |               |
| Age ≥60 y        | 2-dose 2,302,993 | 1379                     | 0.60                             | 90.7 (89.9–91.4)            |               |
|                  | 3-dose 16,910,746| 946                      | 0.06                             |               |
| 1–35 d period    | 2-dose 16,329,153| 15,698                   | 0.96                             | 92.0 (91.6–92.4)            |               |
|                  | 3-dose 27,912,508| 2142                     | 0.08                             |               |
| 36–70 d period   | 2-dose 3,516,117 | 2132                     | 0.61                             | 94.8 (94.1–95.3)            |               |
|                  | 3-dose 11,625,329| 370                      | 0.03                             |               |

Adjusted (matched)a Total population 17,790,141 15,705 0.88 92.6 (92.2–92.9)

Adjusted (GLM model) Total population 89.1 (87.5–90.5)

Abbreviations: CI, confidence interval; GLM, Generalized Linear Model; PCR, polymerase chain reaction; VE, vaccine effectiveness.

aMatched for gender, age group, socioeconomic status, population group, and religiosity, with each group comprising 320,467 persons.
Financial support. The study was carried out (sponsored) on behalf of Maccabi HealthCare Services for the purposes of evaluating the effectiveness of the vaccine among its members.

Potential conflicts of interest. All authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Hopkins Tanne J. Covid-19: FDA panel votes to authorize Pfizer BioNTech vaccine. BMJ 2020; 371:m4799.
2. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15.
3. Leshem E, Wilder-Smith A. COVID-19 vaccine impact in Israel and a way out of the pandemic. Lancet 2021; 397:1783–5.
4. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397:1819–29.
5. Dagan N, Bara N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2020; 384:1412–23.
6. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398:1407–16.
7. Kertes J, Baruch Gez S, Saciuk Y, et al. Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO. medRxiv [Preprint]. Posted online 7 September 2021. doi:10.1101/2021.09.01.21262957.
8. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021; 385:1393–400.
9. Patalon T, Gazit S, Pitzer VE, et al. Short term reduction in the odds of testing positive for SARS-CoV-2; a comparison between two doses and three doses of the BNT162b2 vaccine. medRxiv [Preprint]. Posted online 31 August 2021. doi:10.1101/2021.08.29.21262792.